Seeking Alpha

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, ...
Seeking Alpha

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (BIAF) (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today ...
PharmiWeb

bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients

Poster presented to medical and drug industry conferees at prestigious American Academy of Allergy, Asthma & Immunology ...
TechRadar

Affinity by Canva (2026) review: Three design tools in one, all for free - but is the software an Adobe-killer?

Canva’s Affinity is an impressive tool: its designers managed to cram three apps into one, and not turn it into a convoluted mess. Instead, the interface is clean and well designed, the tools are ...
Nasdaq

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today ...

bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Earl…

SAN ANTONIO, February 25, 2026--bioAffinity Technologies announced validation study with BAMC to assess deep suction sputum ...
Yahoo Finance

Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case Study

SAN ANTONIO, Texas, February 17, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung ...
Nasdaq

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

bioAffinity Technologies: https://www.redchip.com/assets/access/biaf_access In an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight ...
Business Wire

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, ...
Morningstar

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

View source version on businesswire.com: https://www.businesswire.com/news/home/20251114274995/en/ The articles, information, and content displayed on this webpage ...
Morningstar

Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a study of a complex clinical case in which CyPath® Lung’s real-time assessment of the lung microenvironment identified a hidden ...
Business Wire

bioAffinity Technologies Announces Closing of $3.25 Million Offering

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today ...